RxDoctor Payments Data

Charles Curry, MD

Ophthalmology · Rehoboth Beach, DENPI 1528066917

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.8% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 9.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $564, 2.5 times the $227 reported in 2019.

$1,910in general payments, 2019–2025

Across 82 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$189
  • Mallinckrodt Hospital Products Inc.$188
  • Johnson & Johnson Surgical Vision, Inc.$172
  • Tarsus Pharmaceuticals, Inc.$142
  • AbbVie$139
  • Regeneron Healthcare Solutions, Inc.$139
  • plus $940 from 18 others

What the payments were for

  • Food & beverage$1,81095%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,910 in reported general payments places this provider in the 65th percentile of 49 ophthalmology providers in Delaware.

See all ophthalmology providers in Delaware

Medicare billing

Part B allowed, 2024
$937,901
Medicare patients
2,292
Services billed
5,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast51$63,280
LumiganBimatoprost89$53,499
RestasisCyclosporine37$53,042
Prednisolone Acetate972$32,850
MoxifloxacinMoxifloxacin Hcl897$20,887
Ketorolac Tromethamine1,049$18,210
Travoprost70$14,261
Cyclosporine17$10,522
Brimonidine Tartrate68$7,742
TyrvayaVarenicline Tartrate12$7,691
Latanoprost394$7,476
Bromfenac Sodium38$5,706
IlevroNepafenac15$5,405
SimbrinzaBrinzolamide/Brimonidine Tart16$4,743
Brinzolamide15$3,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis$139$106,542126 claims
Bausch & Lomb Americas Inc.Xiidra$70$63,28051 claims
Oyster Point Pharma, Inc.Tyrvaya$41$7,69112 claims
NovartisIlevro$189$5,40515 claims
AlconSimbrinza$132$4,74316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 49 ophthalmology providers in Delaware.

Other ophthalmology in Rehoboth Beach

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →